NASDAQ:NURO - Neurometrix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.89 -0.13 (-12.75 %) (As of 12/12/2018 04:00 PM ET)Previous Close$1.02Today's Range$0.85 - $0.9952-Week Range$0.78 - $2.96Volume248,700 shsAverage Volume302,202 shsMarket Capitalization$6.19 millionP/E Ratio-0.08Dividend YieldN/ABeta0.15 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Asia, the Middle East, Mexico, and internationally. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts. Receive NURO News and Ratings via Email Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NURO Previous Symbol CUSIPN/A Webwww.neurometrix.com Phone781-890-9989 Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio2.39 Price-To-Earnings Trailing P/E Ratio-0.08 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.09 million Price / Sales0.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.85 per share Price / Book0.48 Profitability EPS (Most Recent Fiscal Year)($11.60) Net Income$-12,850,000.00 Net Margins-0.37% Return on Equity-0.90% Return on Assets-0.56% Miscellaneous Employees41 Outstanding Shares7,360,000Market Cap$6.19 million OptionableNot Optionable Neurometrix (NASDAQ:NURO) Frequently Asked Questions What is Neurometrix's stock symbol? Neurometrix trades on the NASDAQ under the ticker symbol "NURO." When did Neurometrix's stock split? How did Neurometrix's stock split work? Shares of Neurometrix reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split. How were Neurometrix's earnings last quarter? Neurometrix Inc (NASDAQ:NURO) announced its quarterly earnings data on Wednesday, October, 17th. The medical device company reported $0.15 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.34. The medical device company had revenue of $3.67 million for the quarter. Neurometrix had a negative net margin of 0.37% and a negative return on equity of 0.90%. View Neurometrix's Earnings History. When is Neurometrix's next earnings date? Neurometrix is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Neurometrix. Has Neurometrix been receiving favorable news coverage? Media coverage about NURO stock has trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neurometrix earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are some of Neurometrix's key competitors? Some companies that are related to Neurometrix include Hancock Jaffe Laboratories (HJLI), Dynatronics (DYNT), DarioHealth (DRIO), Invivo Therapeutics (NVIV), Neovasc (NVCN), CELLECT BIOTECH/S (APOP), Biostage (BSTG), Alliqua Biomedical (ALQA), Presbia (LENS), Valeritas (VLRX), Avinger (AVGR), Atossa Genetics (ATOS), Viatar CTC Solutions (VRTT), United American Healthcare (UAHC) and Cytocore (MDIT). Who are Neurometrix's key executives? Neurometrix's management team includes the folowing people: Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 53)Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 66)Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 57)Mr. Richard J. Thomas, PresMr. Michael J. MacDonald, Sr. VP & GM of Diagnostics Who are Neurometrix's major shareholders? Neurometrix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.90%). Company insiders that own Neurometrix stock include Francis X Mcgillin, Shai Gozani and Thomas T Higgins. View Institutional Ownership Trends for Neurometrix. Which institutional investors are buying Neurometrix stock? NURO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Neurometrix stock in the last two years include Francis X Mcgillin, Shai Gozani and Thomas T Higgins. View Insider Buying and Selling for Neurometrix. How do I buy shares of Neurometrix? Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neurometrix's stock price today? One share of NURO stock can currently be purchased for approximately $0.89. How big of a company is Neurometrix? Neurometrix has a market capitalization of $6.19 million and generates $17.09 million in revenue each year. The medical device company earns $-12,850,000.00 in net income (profit) each year or ($11.60) on an earnings per share basis. Neurometrix employs 41 workers across the globe. What is Neurometrix's official website? The official website for Neurometrix is http://www.neurometrix.com. How can I contact Neurometrix? Neurometrix's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected] MarketBeat Community Rating for Neurometrix (NASDAQ NURO)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 133 (Vote Underperform)Total Votes: 315MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: What are retained earnings?